MedTrace Logo

Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer

NCT05181826 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1200

Last updated 2024-06-14

No results posted yet for this study

Summary

To acquire blood samples from subjects for various purposes, including: i) determining the sensitivity and specificity of select DNA methylation markers for the detection of various types of cancer, ii) identifying benign conditions that may induce false positive or false negative results, and iii) defining the effects of potential interfering substances, such as chemotherapy drugs.

Conditions

Interventions

DIAGNOSTIC_TEST

Multi-analyte Blood Test

Intend for the qualitative detection of DNA methylation markers for the detection of various types of cancer

Sponsors & Collaborators

  • Helio Genomics

    lead INDUSTRY

Principal Investigators

  • Taggert · Helio Health

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-21
Primary Completion
2025-09-30
Completion
2025-12-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05181826 on ClinicalTrials.gov